Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edurne Arriola

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|March 23, 2019
Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive PatternsSergi Clavé, Natalia Rodon, Lara Pijuan, et al.
Clinical Lung Cancer|May 29, 2020
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter StudyTeresa Moran, Alvaro Taus, Edurne Arriola, et al.
Clinical Drug Investigation|July 31, 2024
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung CancerEdurne Arriola, Javier de Castro, Rosario García-Campelo, et al.
Molecular Oncology|September 11, 2024
Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitorsAnna Hernández-Prat, Alejo Rodriguez-Vida, Laura Cardona, et al.
Epigenetics|December 9, 2014
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapyOlga Pernía, Cristobal Belda-Iniesta, Veronica Pulido, et al.
Lung Cancer (Amsterdam, Netherlands)|June 25, 2013
Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancerGerald Schmid-Bindert, Vittorio Gebbia, Frank Mayer, et al.
Future Oncology (London, England)|November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancerBenjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patientsJoana Vidal, Sergi Clavé, Silvia de Muga, et al.
Lung Cancer (Amsterdam, Netherlands)|July 25, 2025
Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)Noemí Reguart, Laura Sampietro-Colom, Òscar Juan-Vidal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I SeminomaStefanie Fischer, Torgrim Tandstad, Matthew Wheater, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|March 23, 2019
Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive PatternsSergi Clavé, Natalia Rodon, Lara Pijuan, et al.
Clinical Lung Cancer|May 29, 2020
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter StudyTeresa Moran, Alvaro Taus, Edurne Arriola, et al.
Clinical Drug Investigation|July 31, 2024
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung CancerEdurne Arriola, Javier de Castro, Rosario García-Campelo, et al.
Molecular Oncology|September 11, 2024
Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitorsAnna Hernández-Prat, Alejo Rodriguez-Vida, Laura Cardona, et al.
Epigenetics|December 9, 2014
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapyOlga Pernía, Cristobal Belda-Iniesta, Veronica Pulido, et al.
Lung Cancer (Amsterdam, Netherlands)|June 25, 2013
Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancerGerald Schmid-Bindert, Vittorio Gebbia, Frank Mayer, et al.
Future Oncology (London, England)|November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancerBenjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patientsJoana Vidal, Sergi Clavé, Silvia de Muga, et al.
Lung Cancer (Amsterdam, Netherlands)|July 25, 2025
Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)Noemí Reguart, Laura Sampietro-Colom, Òscar Juan-Vidal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I SeminomaStefanie Fischer, Torgrim Tandstad, Matthew Wheater, et al.
Pageof 9